Crossing the Canyon in Prostate Cancer
Cancer drugs are hot. Sales of cancer therapies rose from $2.1 billion to $2.9 billion between 1992 and 1996, and even those figures may understate the market. Moreover, the number of cancer drugs in development has also risen dramatically. Perhaps the most fertile area of opportunity: prostate cancer, which is being boosted by an increase in consumer support, leading to faster FDA approvals, and renewed investment from Big Pharma and biotechs.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.